"Use Of Complement Factor D Inhibitor For Treatment Of Geographic Atrophy Secondary To Age-Related Macular Degeneration" in Patent Application Approval Process (USPTO 20240252497).

Alexion Pharmaceuticals Inc. has filed a patent application for a new treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The treatment involves the use of an oral small molecule complement factor D (CFD) inhibitor called Compound 1. This treatment option offers advantages over other therapies by providing a more convenient and accessible option for patients and reducing the need for clinical visits. The patent application discusses various dosing regimens and routes of administration, with the goal of slowing or reversing the progression of GA. The application was filed by Alexion Pharmaceuticals Inc. [Extracted from the article]